Serum levels of mannose-binding lectin and the risk of fever in neutropenic pediatric cancer patients

Pediatric Blood and Cancer

Volumn 49, Issue 1, 2007, Pages 11-16

  Schlapbach, L J ^a   Aebi, C ^a   Otth, M ^a   Luethy, A Ridolfi ^a   Leibundgut, K ^a   Hirt, A ^a   Ammann, Roland A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Chemotherapy; Children; Fever in neutropenia; Infection; Innate immunity; Mannose binding lectin

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; MANNOSE BINDING LECTIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BRAIN TUMOR; CANCER PATIENT; CHILDHOOD CANCER; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK FACTOR; SARCOMA; SCHOOL CHILD;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE SUSCEPTIBILITY; FEMALE; FEVER; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MANNOSE-BINDING LECTIN; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; RISK FACTORS; SARCOMA; SENSITIVITY AND SPECIFICITY;

EID: 34249809759     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21097     Document Type: Article

References (39)

1. Gurney JG, Bondy ML. Epidemiology of childhood cancer. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams & Wilkins; 2006. pp 1-13.
2. Walsh TJ, Roilides E, Groll AH, et al. A Infectious complications in pediatric cancer patients. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams & Wilkins; 2006. pp 1269-1329.
3. Turner MW. Mannose-binding lectin; The pluripotent molecule of the innate immune system. Immunol Today 1996;17:532-540.
4. Neth O, Jack DL, Dodds AW, et al. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000;68:688-693.
5. Jack DL, Klein NJ, Turner MW. Mannose-binding lectin: Targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev 2001;180:86-99.
6. Neth OW, Bajaj-Elliott M, Turner MW, et al. Susceptibility to infection in patients with neutropenia: The role of the innate immune system. Br J Haematol 2005:129:713-722.
7. Fraser DA, Bohlson SS, Jasinskiene N, et al. C1q and MBL, components of the innate immune system, influence monocyte cytokine expression. J Leukoc Biol 2006;80:107-116.
8. Madsen HO, Garred P, Thiel S, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995;155:3013-3020.
9. Minchinton RM, Dean MM, Clark TR, et al. Analysis of the relationship between mannose-binding lectin (MBL) genotype, MBL levels and function in an australian blood donor population. Scand J Immunol 2002;56:630-641.
10. Crosdale DJ, Ollier WE, Thomson W, et al. Mannose binding lectin (MBL) genotype distributions with relation to serum levels in UK caucasoids. Eur J Immunogenet 2000;27:111-117.
11. Dahl M, Tybjaerg-Hansen A, Schnohr P, et al. A population-based study of morbidity and mortality in mannose-binding lectin deficiency. J Exp Med 2004;199:1391-1399.
12. Klein NJ. Mannose-binding lectin: Do we need it? Mol Immunol 2005;42:919-924.
13. Tacx AN, Groeneveld AB, Hart MH. et al. Mannan binding lectin in febrile adults: No correlation with microbial infection and complement activation. J Clin Pathol 2003;56:956-959.
14. Eisen DP, Minchinton RM. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis 2003;37:1496-1505.
15. Bouwman LH, Roos A, Terpstra OT, et al. Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology 2005;129:408-414.
16. Neth O, Hann I, Turner MW, et al. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: A prospective study. Lancet 2001;358:614-618.
17. Peterslund NA, Koch C, Jensenius JC, et al. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 2001;358:637-638.
18. Horiuchi T, Gondo H, Miyagawa H, et al. Association of MBL gene polymorphisms with major bacterial infection in patients treated with high-dose chemotherapy and autologous pbsct. Genes Immun 2005;6:162-166.
19. Mullighan CG, Heatley S, Doherty K, et al. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood 2002;99:3524-3529.
20. Kilpatrick DC, McLintock LA, Allan EK, et al. No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy-related infections. Clin Exp Immunol 2003;134:279-284.
21. Bergmann OJ, Christiansen M, Laursen I, et al. Low levels of mannose-binding lectin do not affect occurrence of severe infections or duration of fever in acute myeloid leukaemia during remission induction therapy. Eur J Haematol 2003;70:91-97.
22. Frakking FN, van de Wetering MD, Brouwer N, et al. The role of mannose-binding lectin (MBL) in paediatric oncology patients with febrile neutropenia. Eur J Cancer 2006;42:909-916.
23. Lausen B, Schmiegelow K, Andreassen B, et al. Infections during induction therapy of childhood acute lymphoblastic leukemia - no association to mannose-binding lectin deficiency. Eur J Haematol 2006;76:481-487.
24. NCT00138736: Phase II study on mannan binding lectin (MBL) substitution in MBL-deficient children with chemotherapy-induced neutropenia, http://www.clinicaltrials.gov. Accessed October 05, 2006.
25. Ammann RA. Hirt A, Ridolfi Lüthy A, et al. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol 2003;41:436-443.
26. Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999;341:312-318.
27. Altman DG. Practical statistics for medical research. London: Chapman & Hall; 1991. 611p.
28. Byar DP. Identification of prognostic factors. In: Buyse ME, Staquet MJ, Sylvester RJ, editors. Cancer clinical trial methods in practice. Oxford: Oxford Medical Publications; 1988. pp 423-443.
29. Ghezzi MC, Raponi G, Angeletti S, et al. Serum-mediated enhancement of TNF-alpha release by human monocytes stimulated with the yeast form of candida albicans. J Infect Dis 1998;178:1743-1749.
30. Schafranski MD, Stier A, Nisihara R, et al. Significantly increased levels of mannose-binding lectin (MBL) in rheumatic heart disease: A beneficial role for MBL deficiency. Clin Exp Immunol 2004;138:521-525.
31. Walsh MC, Bourcier T, Takahashi K, et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol 2005;175:541-546.
32. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol 2005;23:821-852.
33. Fidler KJ, Wilson P, Davies JC, et al. Increased incidence and severity of the systemic inflammatory response syndrome in patients deficient in mannose-binding lectin. Intensive Care Med 2004;30:1438-1445.
34. Dean MM, Minchinton RM, Heatley S, et al. Mannose binding lectin acute phase activity in patients with severe infection. J Clin Immunol 2005;25:346-352.
35. Roos A, Garred P, Wildenberg ME, et al. Antibody-mediated activation of the classical pathway of complement may compensate for mannose-binding lectin deficiency. Eur J Immunol 2004;34:2589-2598.
36. Bouwman LH, Roep BO, Roos A. Mannose-binding lectin: Clinical implications for infection, transplantation, and autoimmunity. Hum Immunol 2006;67:247-256.
37. Schram-Bijkerk D, Doekes G, Boeve M, et al. Nonlinear relations between house dust mite allergen levels and mite sensitization in farm and nonfarm children. Allergy 2006;61:640-647.
38. Mullen CA. Which children with fever and neutropenia can be safely treated as outpatients? Br J Haematol 2001;112:832-837.
39. Ammann RA, Simon A, de Bont ESJM. Low risk episodes of fever and neutropenia in pediatric oncology: Is outpatient oral antibiotic therapy the new gold standard of care? Pediatr Blood Cancer 2005;45:244-247.